Blincyto's label has gradually been extended since 2014, and in December the MHRA approved it as the first immunotherapy for ...

At two Senate confirmation hearings, Kennedy played down his well-publicised questioning of the safety of childhood vaccines ...

A proposed merger of the UK's Poolbeg Pharma with Austrian biotech Hookipa has been called off after the latter abruptly ...

The week has ended with a flurry of M&A in the drug industry, with Cosette Pharmaceuticals agreeing to buy Australia's Mayne ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...

Pharma industry leaders are scheduled to meet with Donald Trump later today to discuss a range of issues affecting the sector ...

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with two PharmaLex experts about navigating complex R&D ...

In his first speech since being appointed Health and Human Services Secretary, Robert F Kennedy Jr pledged to investigate the ...